ELLINK AB (publ) (“CELLINK”) has entered into an agreement with the owners of Scienion Ag (“Scienion”), a German life science company focusing on precision dispensing technologies, to acquire all shares for a purchase price on cash- and debt-free basis of 80M euros (the “Acquisition”). 40M euros will be paid in 2,814,032 newly issued shares of series B in CELLINK (the “Consideration Shares”) and the reminder in cash.
